Product Description
DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/32341336/)
Mechanisms of Action: CD37 Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additional Commercial Interests: Genmab
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Mantle-Cell Lymphoma|Lymphocytic Chronic B-Cell Leukemia|B-Cell Marginal Zone Lymphoma|Diffuse Large B-Cell Lymphoma|Lymphoma, Non-Hodgkin|Follicular Lymphoma|Chronic Lymphoid Leukemia|Lymphoma, B-Cell
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2019-002752-16 |
2019-002752-16 | P2 |
Terminated |
Lymphoma, Non-Hodgkin|Lymphoma, B-Cell |
2023-07-28 |
65% |
2025-07-09 |
Treatments |
NCT04358458 |
GCT3009-01 | P2 |
Terminated |
Lymphocytic Chronic B-Cell Leukemia|Follicular Lymphoma|Diffuse Large B-Cell Lymphoma|Mantle-Cell Lymphoma|Chronic Lymphoid Leukemia|B-Cell Marginal Zone Lymphoma |
2022-11-21 |
65% |
2023-09-14 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/23/2023 |
News Article |
Global Cancer Immunotherapy Market to Surpass US$ 216,792.7 Million by 2030, Says Coherent Market Insights (CMI) |
|
03/03/2022 |
News Article |
Bi-Specific MAbS Global Market Report 2022 |
|
06/23/2021 |
News Article |
Global $10 Billion Bi-Specific MAbS Markets, 2015-2020, 2020-2025F, 2030F |
|
02/23/2021 |
News Article |
Genmab Publishes 2020 Annual Report |
|
12/09/2020 |
PubMed |
Potent Preclinical Efficacy of DuoHexaBody-CD37 in B-Cell Malignancies. |
|
04/28/2020 |
PubMed |
DuoHexaBody-CD37(), a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies. |